Key result
JAK2 V617F mutations occur in ~0.4% of ischemic strokes, marking an actionable, screenable subtype.
Answers are grounded in this paper and cite their sources.
This research uncovers low prevalence of JAK2 mutations in ischemic stroke, suggesting a new screening approach for targeted testing.
Despite low prevalence (0.4%), JAK2 V617F mutation represents a clinically actionable stroke subtype with distinct pathophysiology. The prediction model offers a precision medicine approach, potentially reducing the need for comprehensive genetic testing.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question. JAK2 V617F mutations have a 0.4% prevalence in ischemic stroke, representing a clinically actionable subtype amenable to a pre-screening prediction model.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: